Isabella Lurje1,2, Zoltan Czigany2, Jan Bednarsch2, Nadine Therese Gaisa3, Edgar Dahl3, Ruth Knüchel3, Hannah Miller1,4, Tom Florian Ulmer2, Pavel Strnad5, Christian Trautwein5, Frank Tacke1,5, Ulf Peter Neumann2,6, Georg Lurje2,4. 1. Department of Hepatology and Gastroenterology, Campus Charité Mitte, Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, Berlin, Germany. 2. Department of Surgery and Transplantation, University Hospital RWTH Aachen, Aachen, Germany. 3. Institute of Pathology, University Hospital RWTH Aachen, Aachen, Germany. 4. Department of Surgery, Campus Charité Mitte, Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, Berlin, Germany. 5. Department of Internal Medicine III, University Hospital RWTH Aachen, Aachen, Germany. 6. Department of Surgery, Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands.
Abstract
Background: Perihilar cholangiocarcinoma (pCCA) is a rare primary liver malignancy. Even in patients amenable to surgery, outcomes are often dismal. Here, we aimed to identify prognostic markers for patient outcomes by analyzing functionally relevant single-nucleotide polymorphisms (SNPs) in genes with a role in tumor inflammation and angiogenesis. We analyzed 11 polymorphisms in the inflammation-angiogenesis axis (VEGF, EGF, EGFR, IL-1b, IL-6, CXCL8 (IL-8), IL-10, CXCR1, HIF1A, and COX2 genes) for their prediction of tumor recurrence and survival in pCCA patients undergoing surgery in a curative intent. Methods: Samples were obtained from 111 patients with pCCA undergoing liver resection in curative intent. DNA was extracted and analyzed using polymerase chain reaction-restriction fragment length polymorphism protocols and correlated with patients' outcomes. Results: Out of the assessed variants, only the CXCR1 (also: interleukin-8-receptor alpha - IL-8RA) +860C>G heterozygous polymorphism (rs2234671) was associated with decreased disease-free survival (DFS), cancer-specific survival (CSS), and overall survival (OS) (18/111 (16.2%), median DFS 14 months, log-rank p = 0.007; median CSS 31 months, log-rank p = 0.007; and median OS 6 months, log-rank p = 0.002), compared to the GG genotype (92/111 (82.9%), median DFS 55 months, median CSS 63 months, and median OS 33 months). In the multivariate analysis, +860C>G remained an independent prognostic factor for DFS (adjusted p = 0.008), CSS (adjusted p = 0.001), and OS (adjusted p = 0.001). Conclusion: Genetic variant of CXCR1 +860C>G may serve as a molecular marker for DFS, CSS, and OS in patients undergoing curative-intent surgery for pCCA, indicating that the analysis of SNPs in genes involved in immune-mediated angiogenesis may help to identify patient subgroups at high risk for dismal oncological and overall outcome.
Background: Perihilar cholangiocarcinoma (pCCA) is a rare primary liver malignancy. Even in patients amenable to surgery, outcomes are often dismal. Here, we aimed to identify prognostic markers for patient outcomes by analyzing functionally relevant single-nucleotide polymorphisms (SNPs) in genes with a role in tumor inflammation and angiogenesis. We analyzed 11 polymorphisms in the inflammation-angiogenesis axis (VEGF, EGF, EGFR, IL-1b, IL-6, CXCL8 (IL-8), IL-10, CXCR1, HIF1A, and COX2 genes) for their prediction of tumor recurrence and survival in pCCA patients undergoing surgery in a curative intent. Methods: Samples were obtained from 111 patients with pCCA undergoing liver resection in curative intent. DNA was extracted and analyzed using polymerase chain reaction-restriction fragment length polymorphism protocols and correlated with patients' outcomes. Results: Out of the assessed variants, only the CXCR1 (also: interleukin-8-receptor alpha - IL-8RA) +860C>G heterozygous polymorphism (rs2234671) was associated with decreased disease-free survival (DFS), cancer-specific survival (CSS), and overall survival (OS) (18/111 (16.2%), median DFS 14 months, log-rank p = 0.007; median CSS 31 months, log-rank p = 0.007; and median OS 6 months, log-rank p = 0.002), compared to the GG genotype (92/111 (82.9%), median DFS 55 months, median CSS 63 months, and median OS 33 months). In the multivariate analysis, +860C>G remained an independent prognostic factor for DFS (adjusted p = 0.008), CSS (adjusted p = 0.001), and OS (adjusted p = 0.001). Conclusion: Genetic variant of CXCR1 +860C>G may serve as a molecular marker for DFS, CSS, and OS in patients undergoing curative-intent surgery for pCCA, indicating that the analysis of SNPs in genes involved in immune-mediated angiogenesis may help to identify patient subgroups at high risk for dismal oncological and overall outcome.
Authors: Anthony T Ruys; Bas Groot Koerkamp; Jimme K Wiggers; Heinz-Josef Klümpen; Fiebo J ten Kate; Thomas M van Gulik Journal: Ann Surg Oncol Date: 2013-10-01 Impact factor: 5.344
Authors: Carlos Alfaro; Alvaro Teijeira; Carmen Oñate; Guiomar Pérez; Miguel F Sanmamed; Maria Pilar Andueza; Diego Alignani; Sara Labiano; Arantza Azpilikueta; Alfonso Rodriguez-Paulete; Saray Garasa; Juan P Fusco; Angela Aznar; Susana Inogés; Maria De Pizzol; Marcello Allegretti; Jose Medina-Echeverz; Pedro Berraondo; Jose L Perez-Gracia; Ignacio Melero Journal: Clin Cancer Res Date: 2016-03-08 Impact factor: 12.531
Authors: Ann W Hsing; Lori C Sakoda; Asif Rashid; Gabriella Andreotti; Jinbo Chen; Bin-Shen Wang; Ming-Chang Shen; Bingshu E Chen; Philip S Rosenberg; Mingdong Zhang; Shelley Niwa; Lisa Chu; Robert Welch; Meredith Yeager; Joseph F Fraumeni; Yu-Tang Gao; Stephen J Chanock Journal: Cancer Res Date: 2008-08-01 Impact factor: 12.701
Authors: Georg Lurje; Jessica M Leers; Alexandra Pohl; Arzu Oezcelik; Wu Zhang; Shahin Ayazi; Thomas Winder; Yan Ning; Dongyun Yang; Nancy E Klipfel; Parakrama Chandrasoma; Jeffrey A Hagen; Steven R DeMeester; Tom R DeMeester; Heinz-Josef Lenz Journal: Ann Surg Date: 2010-05 Impact factor: 12.969
Authors: Sang Ho Park; Bibhuti B Das; Fabio Casagrande; Ye Tian; Henry J Nothnagel; Mignon Chu; Hans Kiefer; Klaus Maier; Anna A De Angelis; Francesca M Marassi; Stanley J Opella Journal: Nature Date: 2012-10-21 Impact factor: 49.962
Authors: Isabella Lurje; Zoltan Czigany; Sarah Eischet; Jan Bednarsch; Tom Florian Ulmer; Peter Isfort; Pavel Strnad; Christian Trautwein; Frank Tacke; Ulf Peter Neumann; Georg Lurje Journal: Hepatol Commun Date: 2022-05-26